Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study
Open Access
- 19 January 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1), e0245648
- https://doi.org/10.1371/journal.pone.0245648
Abstract
Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged ≥85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study—a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845). The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2–4, 5–9 and ≥10 medicines—so-called ‘no polypharmacy’, ‘monotherapy’, ‘minor polypharmacy’, ‘polypharmacy’ and ‘hyperpolypharmacy.’ Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5–90.5). Participant characteristics were examined through descriptive statistics. Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4–8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (th centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD. Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.This publication has 62 references indexed in Scilit:
- Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidityAge and Ageing, 2012
- Losing the Ability in Activities of Daily Living in the Oldest Old: A Hierarchic Disability Scale from the Newcastle 85+ StudyPLOS ONE, 2012
- Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008BMC Clinical Pharmacology, 2010
- Engaging the oldest old in research: lessons from the Newcastle 85+ studyBMC Geriatrics, 2010
- Quantitative relationship between the octanol/water partition coefficient and the diffusion limitation of the exchange between adipose and bloodBMC Clinical Pharmacology, 2010
- Sex Differences in Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 2009
- Preventive health care in elderly people needs rethinkingBMJ, 2007
- The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocolBMC Geriatrics, 2007
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- THE INVERSE CARE LAWThe Lancet, 1971